Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets remain buoyant
Tue, 15 Jul 11:30 am

After opening in the green, the Indian indices have remained well above the dotted line in the morning session. Maximum buying interest was seen in banking and Energy stocks while the stocks from pharma and FMCG sectors were witnessing selling pressures.

The BSE-Sensex is trading up 191 points. The NSE-Nifty is trading up 58 points. The BSE Mid Cap index is trading up 1.5% and the BSE Small Cap index is trading up 1.8%. The rupee is trading at 60.18 to the US dollar.

Software stocks are trading mixed today. While Tech Mahindra is leading the gainers; Tata Consultancy Services (TCS) is leading the losers. As per a leading financial daily, India's second largest software firm Infosys, has begun implementing innovative HR policies to retain talent as it grapples with high attrition. The company has adopted a quarterly promotion cycle for top performing employees and has reduced the variable pay component in salaries. This has led to greater certainty in terms of career progression for its staff. Also the company has put in place a fast track programme for accelerating the career path for high performers. These measures are expected to have an effect over the next 2-3 quarters. In 1QFY15 the attrition rate of the company stood at an all time high of 19.5%. Infosys is trading up 0.2% today.

Majority of the Indian pharma stocks are trading in the green today with Orchid chemicals and Dishman Pharma leading the gainers. As per a financial daily, the government has proposed to revise the prices of 37 new drugs and 13 new strengths of existing drugs (which are already under price control). Reportedly, the government is mulling to cut the prices of these drugs by 10-35%. As per the AIOCD estimates, this step will impact aggregate revenues from these drugs by approx 12% on an average. To begin with the NPPA will examine inter-brand price difference in eight single-ingredient drug segments Vis; oncology, HIV/AIDS, tuberculosis, malaria, asthma, immunology, cardiology and diabetes. The current round of notifications covers two therapies as of now that are cardiology and diabetes. The other six are expected to be taken up some time later. It is also reported that more therapies could be added and also combination drugs could come under the pricing purview. These instances indicate that Indian pharma companies might have to face more challenges on the pricing front.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.